Last checked at 9 Jan 2012 15:42
Port Erin Biopharma Investments Limited
("the Company")
Net Asset Value calculation for the first trading quarter to 31 December 2011
Tom Winnifrith, Chief Investment Officer, commented: -
"The maiden Net Asset Value calculation for the Company as at close of business on 31 December 2011 is 8.56 pence per share, with 33.9% of the money raised at IPO still to be invested. This outcome is particularly pleasing considering the uncertainty of the current market conditions and that the net cash available for investment after listing costs was £2.75 million - the NAV immediately after listing on 15 September 2011 was 8.33 pence share."
| Unaudited 15 September to 31 December 2011 £ | |
Fixed Assets |
|
|
| Investments
| 1,809,046 |
Current Assets |
|
|
| Sundry Debtors | 0 |
| Uninvested cash
| 1,016,033 |
Current Liabilities |
|
|
| Creditors: amounts due
| 0 |
|
| 2,825,079 |
Capital and Reserves |
|
|
| Share Capital | 3,000,003 |
| Share Premium | 997 |
| Capital reserve - realised | 0 |
| Capital reserve - unrealised | 0 |
| Revenue reserve
| (175,921) |
| 2,825,079 | |
| ||
Shares in Issue
| 33,000,000 | |
Net Asset Value per share
| 8.56 pence |
| Detailed Portfolio |
|
Company | Value @ 31/12/11 | Portfolio % |
Arrowhead Research Corp. | 275,644 | 15.2% |
Plethora Solutions Holdings plc | 111,319 | 6.2% |
Smith & Nephew plc | 91,712 | 5.1% |
Novo-Nordisk A/S | 81,817 | 4.5% |
Ariad Pharmaceuticals Inc. | 81,783 | 4.5% |
Pfizer Inc. | 77,145 | 4.3% |
Biogen Idec Inc. | 72,045 | 4.0% |
Eli Lilly & Co. | 71,369 | 3.9% |
Amgen Inc. | 70,753 | 3.9% |
GlaxoSmithKline plc | 69,966 | 3.9% |
H. Lundebeck A/S | 68,210 | 3.8% |
Roche Holding AG | 67,875 | 3.8% |
Sanofi S.A. | 66,615 | 3.7% |
Gilead Sciences Inc. | 66,324 | 3.7% |
Medivation Inc. | 65,738 | 3.6% |
Seattle Genetics Inc. | 54,155 | 3.0% |
Cepheid Inc. | 53,513 | 3.0% |
Astellas Pharma Inc. | 53,381 | 3.0% |
Synergy Pharmaceuticals Inc. | 53,378 | 3.0% |
Protalix Biotherapeutics Inc. | 49,329 | 2.7% |
Alkermes plc | 47,232 | 2.6% |
Kamada Ltd. | 44,938 | 2.5% |
Siga Technologies Inc. | 37,419 | 2.1% |
Pharmathene Inc. | 34,434 | 1.9% |
Methylgene Inc. | 23,962 | 1.3% |
Star Scientific Inc. | 18,988 | 1.0% |
ENDS
For further information, please contact:
Port Erin Biopharma Investments Ltd | Libertas Capital Corporate Finance Limited | Rivington Street Corporate Finance Limited |
The Company | Nomad | Broker |
Tom Winnifrith +44 7624 355306 | Sandy Jamieson +44 207 569 9650 | Jon Levinson +44 207 562 3350 |